No increase in outcomes (death, diabetes, bone fractures, non-fatal cardiovascular disease, cancer, autoimmune disease, and infectious disease) was observed in patients with MIC. MAC carriers, drug-induced and idiopathic hyperprolactinemia groups with an increased risk of death. The increased risk was not related to PRL levels. Here, PRL is linked to autoimmune disease.